# GLP-1-agonisten gekoppeld aan lagere sterfte bij vasculaire dementie — retrospectieve cohortstudie

*geplaatst 2026-11-18 · Hartfalen · Acta neurologica Belgica · doi 10.1007/s13760-026-03229-z · https://hartvaat.nl/2026/11/10/glp-1-agonisten-gekoppeld-aan-lagere-sterfte-bij-vasculaire-dementie-retrospecti/*

In een retrospectieve cohortstudie met propensity-score matching (n=1.226) werd het gebruik van GLP-1-agonisten bij patiënten met vasculaire dementie geanalyseerd. Gebruikers hadden een significant lager risico op sterfte na 1, 3 en 5 jaar (respectievelijk HR 0,49; 0,58 en 0,53) en minder ziekenhuisopnames. Deze bevindingen suggereren een potentieel extra voordeel van GLP-1-agonisten naast hun bekende cardiometabole werking, maar bevestigen de noodzaak van prospectieve gerandomiseerde trials.

## English: Association of GLP-1 receptor agonist use with mortality and healthcare utilization in patients with vascular dementia.

In a propensity score matched retrospective cohort study (n=1,226), GLP-1 receptor agonist use in patients with vascular dementia was associated with significantly lower mortality at 1, 3, and 5 years (HRs 0.49, 0.58, and 0.53) and reduced hospital admissions. While observational, the findings suggest potential systemic benefits of GLP-1 agonists beyond glycemic control and cardiovascular risk, warranting prospective randomized trials.

## Abstract (original, from the publication)

BACKGROUND AND OBJECTIVES: Patients with vascular dementia (VD) have high mortality and frequent acute care use, and no treatment has been shown to improve these outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a lower incidence of dementia and with cardiovascular benefit in type 2 diabetes, but their association with clinical outcomes in patients with established VD is unknown. METHODS: This retrospective cohort study using a national database identified patients with VD from 2016 to 2025. Patients receiving GLP-1RAs within one month of diagnosis were propensity-score matched with non-users (n = 613 per group). Primary outcome was mortality at 1, 3, and 5 years; secondary outcomes included hospitalizations and emergency visits. RESULTS: GLP-1RA use was associated with lower risk of mortality at 1 year (8.7% vs. 15.9%; HR 0.49, 95% CI 0.34-0.71), 3 years (23.3% vs. 33.8%; HR 0.58, 95% CI 0.44-0.76), and 5 years (34.4% vs. 54.3%; HR 0.53, 95% CI 0.41-0.69) (all p < 0.001). In addition, GLP-1RA use was associated with lower risk of inpatient admissions and emergency visits. CONCLUSION: GLP-1RA use in patients with VD was associated with lower risk of mortality and healthcare utilization. These beneficial associations warrant prospective randomized trials.

Auteurs: Daniel Mandel, Pranjal Rai, Huanwen Chen, Jay Kakadiya, Girish Bathla, Matthew K Mcintyre, Shahrzad Latifi, Brian Connolly, Hamza A Salim, Ahmed Y Azzam, Muhammed Amir Essibayi, Vivek S Yedavalli, Majid Khan, Adam A Dmytriw, David J Altschul, Marco Colasurdo, Ajay Malhotra, Dheeraj Gandhi, Dhairya A Lakhani

---
Bron: Acta neurologica Belgica, https://doi.org/10.1007/s13760-026-03229-z. Bijgewerkt 2026-11-11T02:40:58Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.
